Welcome to Plasma City—a place where you can build your foundation for success with ALPHANATE

ALPHANATE is a trusted treatment for patients with hemophilia A or von Willebrand disease (VWD)1

Learn about ALPHANATE

ALPHANATE is a human plasma-derived factor complex that contains both factor VIII (FVIII) and von Willebrand factor (VWF).1

 

ALPHANATE is designed to meet the needs of a variety of patients.1

 

Since product launch in 1997, there has never been a confirmed case of virus or prion transmission with ALPHANATE.

 

ALPHANATE IS MADE WITH A 10-STEP PLASMA SAFETY PROCESS

ALPHANATE is manufactured using 10 steps to safety with full traceability through the entire process from donor to patient.

ALPHANATE 10 STEPS TO SAFETY IMAGE
ALPHANATE PLASMA DONATION AND DONOR SELECTION PROCESS
ALPHANATE PLASMA MANUFACTURING PROCESS
ALPHANATE PLASMA SAFTEY AND PURITY PROCESS]

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Learn More

ALPHANATE IS MADE WITH A 10-STEP PLASMA SAFETY PROCESS

ALPHANATE is manufactured using 10 steps to safety with full traceability through the entire process from donor to patient.

ALPHANATE 10 STEPS TO SAFETY IMAGE
HIDE
ALPHANATE PLASMA DONATION AND DONOR SELECTION PROCESS
ALPHANATE PLASMA MANUFACTURING PROCESS
ALPHANATE PLASMA SAFTEY AND PURITY PROCESS]

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Learn More

ALPHANATE PATIENT SUPPORT AND RESOURCES

FACTORS FOR HEALTH SUPPORT GROUP LOGO

Factors for Health

A comprehensive patient support and assistance program.

Talk to your doctor

The Doctor Discussion Guide will give you information to help you ask key questions and have an informative conversation with your doctor.

ALPHANATE GRIFOLS GEAR TRAVEL KIT IMAGE

Grifols Gear travel kit

The Grifols Gear travel kit makes infusions easier when you are on the go.

Hemophilia A & VWD Resources

Check out these helpful links for people with bleeding disorders.

Learn More

LIVING WITH HEMOPHILIA A

Indications

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery
Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.

Reference:
  1. ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) Prescribing Information. Grifols.